Pavmed Inc. · NASDAQ:PAVM
Pavmed — Marcum Microcap Conference 2016
22 slides from Pavmed's conference presentation, Jun 2, 2016
Slide 1: Marcum Microcap Conference
Marcum Microcap Conference June 2, 2016 New York, NY LISHAN AKLOG, MD Chairman & CEO Nasdaq:PAVMU 1
Slide 2: Disclaimers
Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but
Slide 3: Innovative multi-product medical device company
Innovative multi-product medical device company Leadership team of entrepreneurs with a strong track record of value creation Unique, proven business model focused on capital efficiency and speed to market Deep, expanding pipeline of innovative products across a broad spectrum of clinical conditions
Slide 4: Leadership team with strong record of value creation
Leadership team with strong record of value creation LISHAN AKLOG, MD CHAIRMAN & CEO A.B. Physics, magna cum laude Phi Beta Kappa M.D., cum laude General Surgery Resident Cardiothoracic Surgery Resident Assistant Professor Associate Surgeon Associate Chief of Cardiac Surgery Assistant Professor Dire
Slide 5: Leadership team's prior track record of success
Leadership teamʼs prior track record of success ANGIOVAC® Endovascular device to move large lots and other material VENOPAX® Endoscopic vessel harvest device for coronary bypass surgery HOUDINI® Device to treat chronic total occlusion of peripheral arteries KALEIDOSCOPE Reversible inferior vena cava
Slide 6: Leadership team's track record of success
Leadership teamʼs track record of success Nasdaq:PAVMU 6
Slide 7: Proven record of capital efficiency and speed to market
Proven record of capital efficiency and speed to market TIME AND CAPITAL TO FDA CLEARANCE PAVmed Model 23 Months Typical Company 61 Months 0 12 24 36 48 60 Months PAVmed Model $3M Typical Company $31M $0 $10,000,000 $20,000,000 $30,000,000 Dollars * Typical Company data from Markower, et al. FDA Imp
Slide 8: Project selection criteria drive commercial opportunity
Project selection criteria drive commercial opportunity Reimbursement Profile Technology Profile Unmet Clinical Need Regulatory Profile High Margin Product Attractive Market Commercial Opportunity Nasdaq:PAVMU 8
Slide 9: Key business processes drive capital efficiency and speed
Key business processes drive capital efficiency and speed Outsourced Best-in-class Process Experts Parallel Development Processes Regulatory Strategy Capital Efficiency Speed To Market Light Infrastructure Low Fixed Costs Flexible Commercialization Strategy Nasdaq:PAVMU 9
Slide 10: Lead products provide near-term value creation opportunities
Lead products provide near-term value creation opportunities PortIO Long-term Implantable Vascular Access Device CarpX Percutaneous Device to Treat Carpal Tunnel Syndrome Caldus Disposable Tissue Ablation Devices NextCath Self-Anchoring Short-Term Catheters NextFlo Highly Accurate Disposable Infusio
Slide 11: Lead products provide near-term value creation opportunities
Lead products provide near-term value creation opportunities PRODUCT ADDRESSABLE MARKET REGULATORY PATH COMMERCIALIZATION INITIAL CHANNEL TARGET DATE PortIO Long-term Implantable Vascular Access Devices $500M/$50M 510(k) Independent Distributors Q2 2017 Caldus Disposable Tissue Ablation Devices $200
Slide 12: Long-term implantable vascular access ports
Long-term implantable vascular access ports Commonly known as “Port-a-Caths” Most common indications Chemotherapy Intravenous nutrition Other long-term medication regimens Hemophilia treatments Antibiotics New biologics Market ~400,000 US patients/year in 2012* Estimated $400-500 million market CAGR
Slide 13: Unmet clinical need - current device limitations
Unmet clinical need ‒ current device limitations OCCLUSIONS ~30% of patients Potentially more serious complications (DVT, PE) Requires clot-busting medications or a repeat procedure Significant economic burden POOR VEINS >10% of patients Kidney failure patients on dialysis Prior chemotherapy or othe
Slide 14: PortIO - The PAVmed Solution
PortIO ‒ The PAVmed Solution PortIOTM Implantable INTRAOSSEOUS Vascular Access Port NO INTRAVASCULAR COMPONENT INTRAOSSEOUS INFUSION Intraosseous = into the bone marrow Well established access site for ACUTE Infusions Pediatric ER/Military Trauma Good bioequivalence to IV Infusions Has not previousl
Slide 15: PortIO - The PAVmed Solution
PortIO ‒ The PAVmed Solution Fewer Complications Fewer occlusions Potential for fewer, less serious infections More Cost Effective Fewer occlusions No need for regular flushes No radiographic confirmation Shift procedures less expensive locale Less Invasive Near percutaneous insertion/removal More V
Slide 16: Carpal Tunnel Syndrome
Carpal Tunnel Syndrome Estimated prevalence 3-8% of adults = ~5M >3M office visits per year Most common cumulative trauma disorder Most common occupational injury Most common cause of lost work days Billions of dollars in workmanʼs comp Carpal Tunnel Surgery Over 600,000 US procedures per year Tradi
Slide 17: Unmet clinical need - current device limitations
Unmet clinical need ‒ current device limitations TRADITIONAL SURGERY IS INVASIVE 2 inch incision Surgical procedure Post-operative Pain 3-4 month recovery ENDOSCOPIC SURGERY IS LESS EFFECTIVE Higher recurrence Higher reoperation rate Increased nerve injury Nasdaq:PAVMU 17
Slide 18: CarpX - The PAVmed Solution
CarpX ‒ The PAVmed Solution PERCUTANEOUS device to treat Carpal Tunnel Syndrome NO SURGICAL INCISION CARPX Balloon catheter with bipolar cutting electrode Inserted into tunnel over a guidewire under ultrasound guidance Cleanly cuts ligament from inside out in <1.5 sec No visible injury to surroundin
Slide 19: CarpX - The PAVmed Solution
CarpX ‒ The PAVmed Solution Less Invasive Truly percutaneous No surgical incision or dissection More Cost Effective Shift procedures interventional lab or office Shorten procedural times Fewer Complications Better nerve protection Greater lateral dissection may decrease recurrence rates Expanded Mar
Slide 20: Near- and long-term opportunities for value creation
Near- and long-term opportunities for value creation Caldus RND CE Clearance CarpX Commercialization Caldus General Commercialization NextCath, NextFlo Commercialization PortIO Commercialization Caldus General FDA Submission CarpX FDA Submission NextCath, NextFlo FDA Submission PortIO FDA Submission
Slide 21: Corporate Highlights
Corporate Highlights Founded June 2014 Nasdaq IPO Completed April 28, 2016 1,060,000 Units (1 share, 1 warrant) Sold at $5.00 per Unit $5,300,000 gross proceeds Capital Structure Total Shares Outstanding 13,310,000 Total Warrants Outstanding 10,522,741 Units split into Shares/Warrants July 28, 2016
Slide 22: PAVmed - Innovating at the speed of life
<< PAVmed INNOVATING AT THE SPEED OF LIFE™ NasSdaq:PAVMU